Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

Exclusion Criteria

• •1. Previous treatment with Nectin-4-targeted drugs (including clinical trials);
• •2. Inability to complete PET/CT or SPECT/CT examinations (including inability to lie flat, claustrophobia, radiophobia, etc.);
• •3. Participation in drug or device clinical studies within 4 weeks prior to the first dose;
• •4. Presence of severe or uncontrolled underlying diseases, including but not limited to:
• •1. NYHA Class II or higher congestive heart failure, or severe arrhythmia requiring medication;
• •2. Severe cardiovascular/cerebrovascular or valvular diseases;
• •3. Poorly controlled diabetes or hypertension;
• •5. Inability to tolerate intravenous administration or difficulty with venipuncture (e.g., history of needle or blood phobia);
• •6. Active infection within 4 weeks prior to the first dose;
• •7. Women who are planning pregnancy, currently pregnant, or breastfeeding;
• •8. Allergy to radioactive rays or other severe allergic history;
• •9. History of neurological metastasis with associated symptoms;
• •10. Concurrent other malignancies;
• •11. Undergone general anesthesia surgery within 4 weeks prior to the first dose;
• •12. Other conditions deemed by the investigator as unsuitable for inclusion in the clinical study.